Winston Pharmaceuticals, Inc. was formed when the privately held firm Winston Labs - focused to pain and headache treatment - agreed to merge with publicly held shell firm - Getting ready. The new entitiy was a research-based specialty pharmaceutical company engaged in the discovery, development and commercialization of pain management products. The Companys core technology affects the functioning of certain neurotransmitters that control and mediate pain transmission. Based on this technology, it is developing products that reduce pain transmission from peripheral receptors along nerve pathways to the brain. It is focused on pain indications, such as neuropathic pain syndromes, chronic daily headache, migraine headache and osteoarthritis. It has developed multiple formulations and uses of Civamide and doxepin hydrochloride, two agents that affect a variety of neuroactive chemical transmitters that convey primary sensory input (pain) from the periphery to the central nervous system. Civamide is a transient receptor potential vanilloid-1 receptor modulator, and doxepin hydrochloride is a potent histamine receptor blocker and serotonin reuptake inhibitor. Formerly doing business as Winston Laboratories, Inc. the firm changed its name to Winston Pharmaceuticals, Inc. in November 2008. Though still listed, website shows nothing new since 2012 with only nominal trading in several years. Principals also now have other nstitutional affiliations.
